Hematological malignancies in connective tissue diseases

Chronic inflammation has profound tumor-promoting effects. Inflammatory cells are the key players in immunosurveillance against tumors, and immunosuppression is known to increase the risk of tumors. Autoimmune diseases, which manifest as loss of self-tolerance and chronic immune dysregulation, provide a perfect environment for tumor development. Aside from managing the direct inflammatory consequences of autoimmune pathogenesis, cancer risk profiles should be considered as a part of a patient's treatment. In this review, we describe the various associations of malignancies with autoimmune diseases, specifically systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and Sjögren's syndrome, as well as discuss the mechanisms contributing to the pathogenesis of both disorders.

[1]  Y. Shoenfeld,et al.  Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival , 2019, Oncoimmunology.

[2]  A. Alunno,et al.  One year in review 2018: pathogenesis of rheumatoid arthritis. , 2018, Clinical and experimental rheumatology.

[3]  J. Gómez-Reino,et al.  Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. , 2017, Seminars in arthritis and rheumatism.

[4]  M. Ehrenfeld,et al.  Cancer and autoimmune diseases. , 2017, Autoimmunity reviews.

[5]  C. Vacchi,et al.  Haematological Malignancies in Systemic Sclerosis Patients: Case Reports and Review of the World Literature , 2017, Case reports in rheumatology.

[6]  A. Selva-O'Callaghan,et al.  Novel risk factors related to cancer in scleroderma. , 2017, Autoimmunity reviews.

[7]  A. López-Guillermo,et al.  Characterization and risk estimate of cancer in patients with primary Sjögren syndrome , 2017, Journal of Hematology & Oncology.

[8]  C. Brunet,et al.  Rheumatologic Manifestations of Hematologic Neoplasms. , 2017, Current rheumatology reviews.

[9]  S. Tiosano,et al.  Coexistent malignant conditions in rheumatoid arthritis – A population‐based cross‐sectional study , 2017, International journal of clinical practice.

[10]  S. Tiosano,et al.  Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study , 2017, Immunologic Research.

[11]  J. Mosak,et al.  Systemic Sclerosis and Malignancy: A Review of Current Data , 2016, Journal of clinical medicine research.

[12]  L. See,et al.  Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases , 2016, Medicine.

[13]  F. Yıldız,et al.  Risk factors for malignancy in systemic sclerosis patients , 2016, Clinical Rheumatology.

[14]  X. Mariette,et al.  Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome , 2016, Arthritis & rheumatology.

[15]  A. Yoshizaki B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets , 2016, The Journal of dermatology.

[16]  Ami A. Shah,et al.  Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening , 2015, Current opinion in rheumatology.

[17]  S. Bernatsky,et al.  Malignancies in systemic lupus erythematosus: a 2015 update , 2015, Current opinion in rheumatology.

[18]  M. Hochberg,et al.  Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis , 2015, Arthritis Research & Therapy.

[19]  L. Teuwen,et al.  Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study , 2015, Clinical Rheumatology.

[20]  C. Chizzolini,et al.  The role of the acquired immune response in systemic sclerosis , 2015, Seminars in Immunopathology.

[21]  A. Tzioufas,et al.  Clinical picture, outcome and predictive factors of lymphoma in Sjӧgren syndrome. , 2015, Autoimmunity reviews.

[22]  D. Kanduc,et al.  EBV-Associated Cancer and Autoimmunity: Searching for Therapies , 2015, Vaccines.

[23]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[24]  B. Houston,et al.  T cell ALL presenting as seropositive rheumatoid arthritis: case report and review of the literature on seropositive paraneoplastic arthritis , 2015, Clinical Rheumatology.

[25]  M. Koutsilieris,et al.  B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. , 2014, Journal of autoimmunity.

[26]  A. Manfredi,et al.  Radiological thymus alterations in systemic sclerosis: our experience and a review of the literature. , 2014, Rheumatology.

[27]  Y. Zu,et al.  Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Ami A. Shah,et al.  Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma , 2014, Arthritis Research & Therapy.

[29]  Yuchen Jiao,et al.  Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer , 2014, Science.

[30]  D. Gladman,et al.  Lymphoma risk in systemic lupus: effects of disease activity versus treatment , 2012, Annals of the rheumatic diseases.

[31]  J. Andreu,et al.  Identification of lymphoma predictors in patients with primary Sjögren’s syndrome: a systematic literature review and meta-analysis , 2014, Rheumatology International.

[32]  M. Colombo,et al.  Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma. , 2014, Cancer Discovery.

[33]  K. Bogunia-Kubik,et al.  [Tumors in rheumatic diseases]. , 2013, Postepy higieny i medycyny doswiadczalnej.

[34]  X. Mariette,et al.  Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome. , 2013, Arthritis and rheumatism.

[35]  D. Gladman,et al.  Epigenetics and lupus , 2012, Arthritis Research & Therapy.

[36]  G. Houen,et al.  Epstein-Barr Virus in Systemic Autoimmune Diseases , 2013, Clinical & developmental immunology.

[37]  D. Sugiyama,et al.  Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. , 2013, Arthritis and rheumatism.

[38]  K. Ohshima,et al.  Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein–Barr virus, and clonality are important predictors of disease progression and regression , 2013, European journal of haematology.

[39]  G. Verleden,et al.  Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors , 2013, Leukemia & lymphoma.

[40]  W. Dixon,et al.  Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population , 2012, Rheumatology.

[41]  A. Loft,et al.  Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry , 2012, Annals of the rheumatic diseases.

[42]  V. Bojinca,et al.  Rheumatic diseases and malignancies. , 2012, Maedica.

[43]  A. Sisó-Almirall,et al.  [Primary Sjögren syndrome]. , 2012, Praxis.

[44]  G. Szücs,et al.  Malignancies associated with systemic sclerosis. , 2012, Autoimmunity reviews.

[45]  M. Suarez‐Almazor,et al.  Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. , 2012, JAMA.

[46]  T. Barnetche,et al.  Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. , 2012, Clinical and experimental rheumatology.

[47]  I. Colmegna,et al.  Current Understanding of Rheumatoid Arthritis Therapy , 2012, Clinical pharmacology and therapeutics.

[48]  A. Sisó-Almirall,et al.  Primary Sjögren syndrome , 1986, BMJ : British Medical Journal.

[49]  D. Solomon,et al.  Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. , 2012, Arthritis and rheumatism.

[50]  M. Maroun,et al.  Serologic laboratory findings in malignancy. , 2011, Rheumatic diseases clinics of North America.

[51]  Paul Emery,et al.  Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis , 2011, Annals of the rheumatic diseases.

[52]  E. Keystone Does Anti-Tumor Necrosis Factor-α Therapy Affect Risk of Serious Infection and Cancer in Patients with Rheumatoid Arthritis?: A Review of Longterm Data , 2011, The Journal of Rheumatology.

[53]  H. Amital,et al.  Anti-TNF therapy: safety aspects of taking the risk. , 2011, Autoimmunity reviews.

[54]  Chun-Ying Wu,et al.  The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. , 2011, Arthritis and rheumatism.

[55]  A. Taniguchi,et al.  Incidence of malignancy in Japanese patients with rheumatoid arthritis , 2011, Rheumatology International.

[56]  P. Mehta,et al.  TNF-α inhibitors : are they carcinogenic ? , 2010 .

[57]  A. Gottlieb,et al.  Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis , 2010, The Journal of Rheumatology.

[58]  H. Sørensen,et al.  Systemic sclerosis and the risk of cancer: a nationwide population‐based cohort study , 2010, The British journal of dermatology.

[59]  J. Askling,et al.  Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. , 2010, Arthritis and rheumatism.

[60]  L. Kovács,et al.  Malignancies in systemic lupus erythematosus. , 2010, Autoimmunity reviews.

[61]  G. Burmester,et al.  Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT , 2010, Arthritis research & therapy.

[62]  N. Harris,et al.  Immunomodulator agent-related lymphoproliferative disorders , 2009, Modern Pathology.

[63]  S. Bernatsky,et al.  Malignancy in systemic lupus erythematosus: what have we learned? , 2009, Best practice & research. Clinical rheumatology.

[64]  M. Lebwohl,et al.  Treatments for psoriasis and the risk of malignancy. , 2009, Journal of the American Academy of Dermatology.

[65]  F. Balkwill Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[66]  B. Dijkmans,et al.  Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases , 2009, Annals of the rheumatic diseases.

[67]  O. Landgren,et al.  Autoimmunity and hematologic malignancies: associations and mechanisms , 2009, Leukemia & lymphoma.

[68]  D. M. van der Heijde,et al.  Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research , 2008, Annals of the rheumatic diseases.

[69]  J. K. Pedersen,et al.  Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources , 2009, Rheumatology International.

[70]  G. Giles,et al.  Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. , 2008, Arthritis and rheumatism.

[71]  D. Solomon,et al.  The relationship between cancer and rheumatoid arthritis: still a large research agenda , 2008, Arthritis research & therapy.

[72]  K. Hemminki,et al.  Cancer risk in hospitalized rheumatoid arthritis patients. , 2008, Rheumatology.

[73]  M. Hochberg,et al.  A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis , 2008, Arthritis research & therapy.

[74]  P. Tak,et al.  Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.

[75]  F. Wolfe,et al.  Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. , 2007, Arthritis and rheumatism.

[76]  A. Ekbom,et al.  A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study , 2007, Annals of the rheumatic diseases.

[77]  F. Wolfe,et al.  The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. , 2007, Arthritis and rheumatism.

[78]  J. Avorn,et al.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[79]  A. Iliadou,et al.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[80]  N. Hardwick,et al.  Multiple haematological malignancies in a patient with rheumatoid arthritis without exposure to disease modifying therapy , 2006, Annals of the rheumatic diseases.

[81]  L. Jacobsson,et al.  Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors , 2005, Annals of the rheumatic diseases.

[82]  J. Avorn,et al.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[83]  Theodore R Holford,et al.  Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. , 2006, The Lancet. Oncology.

[84]  W. Miesbach,et al.  Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies , 2006, Clinical Rheumatology.

[85]  E. Zintzaras,et al.  The risk of lymphoma development in autoimmune diseases: a meta-analysis. , 2005, Archives of internal medicine.

[86]  D. Gladman,et al.  Non-Hodgkin’s lymphoma in systemic lupus erythematosus , 2005, Annals of the rheumatic diseases.

[87]  A. Tzioufas,et al.  Hepatitis C virus, Sjögren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. , 2005, Autoimmunity reviews.

[88]  S. Fischer,et al.  Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. , 2004, Journal of the National Cancer Institute.

[89]  G. Salles,et al.  Prevalence and pattern of antinuclear autoantibodies in 347 patients with non‐Hodgkin's lymphoma , 2003, British journal of haematology.

[90]  L. Klareskog,et al.  Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. , 2003, Arthritis and rheumatism.

[91]  James M Robins,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[92]  D. Isenberg,et al.  Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. , 2000, Rheumatology.

[93]  M. Jewett,et al.  Cyclophosphamide-induced bladder cancer. , 1999, The Canadian journal of urology.

[94]  D. Knowles Immunodeficiency-associated lymphoproliferative disorders. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[95]  H. Nishimura,et al.  Susceptibility alleles for aberrant B-1 cell proliferation involved in spontaneously occurring B-cell chronic lymphocytic leukemia in a model of New Zealand white mice. , 1998, Blood.

[96]  S. Schwartzman,et al.  Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. , 1997, Seminars in arthritis and rheumatism.

[97]  D. Symmons,et al.  Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. , 1996, British journal of rheumatology.

[98]  J. Lacy,et al.  Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  P. Banks,et al.  Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome. , 1996, Seminars in arthritis and rheumatism.

[100]  H. Dombret,et al.  Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection. , 1995, The Journal of rheumatology.

[101]  R. Warnke,et al.  Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. , 1993, The New England journal of medicine.

[102]  M. Newkirk,et al.  Reversible lymphomas. , 1993, The New England journal of medicine.

[103]  S. Hirose,et al.  Major histocompatibility complex controls clonal proliferation of CD5+ B cells in H‐2‐congenic New Zealand mice: a model for B cell chronic lymphocytic leukemia and autoimmune disease , 1991, European journal of immunology.

[104]  C. Werning [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.

[105]  R. Hoover,et al.  Increased risk of lymphoma in sicca syndrome. , 1978, Annals of internal medicine.